ST1571: a paradigm for clinical trials of molecularly targeted agents.

Suppr

超能文献

作者信息

Druker B J

机构信息

Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland 97201, USA.

出版信息

Biomed Pharmacother. 2001 Nov;55(9-10):529-30. doi: 10.1016/s0753-3322(01)00137-8.

DOI:10.1016/s0753-3322(01)00137-8

PMID:11769961

Abstract

摘要

相似文献

ST1571: a paradigm for clinical trials of molecularly targeted agents.

Biomed Pharmacother. 2001 Nov;55(9-10):529-30. doi: 10.1016/s0753-3322(01)00137-8.

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S77-8. doi: 10.1007/s002800100310.

Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?

J Natl Cancer Inst. 2002 Nov 20;94(22):1660-1. doi: 10.1093/jnci/94.22.1660.

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

J Cancer Res Clin Oncol. 2004 Feb;130(2):59-72. doi: 10.1007/s00432-003-0502-2. Epub 2003 Nov 7.

STI571 (Gleevec) as a paradigm for cancer therapy.

Trends Mol Med. 2002;8(4 Suppl):S14-8. doi: 10.1016/s1471-4914(02)02305-5.

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.

Curr Opin Oncol. 2000 Nov;12(6):594-7. doi: 10.1097/00001622-200011000-00013.

Promising clinical trials on kinase inhibitor.

Trends Cell Biol. 2001 Mar;11(3):110. doi: 10.1016/s0962-8924(01)01927-4.

STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?

Tumori. 2001 Nov-Dec;87(6):S10-2.

Imatinib mesylate.

Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241.

[New molecular therapy options in hematology and oncology, exemplified by STI571].

Internist (Berl). 2001 Dec;42(12):1591-7. doi: 10.1007/s001080170011.

引用本文的文献

Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study.

Transl Gastroenterol Hepatol. 2018 Mar 14;3:16. doi: 10.21037/tgh.2018.03.01. eCollection 2018.

Targeting tumor metastases: Drug delivery mechanisms and technologies.

J Control Release. 2015 Dec 10;219:215-223. doi: 10.1016/j.jconrel.2015.09.042. Epub 2015 Sep 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

ST1571: a paradigm for clinical trials of molecularly targeted agents.

Biomed Pharmacother. 2001 Nov;55(9-10):529-30. doi: 10.1016/s0753-3322(01)00137-8.

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S77-8. doi: 10.1007/s002800100310.

Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?

J Natl Cancer Inst. 2002 Nov 20;94(22):1660-1. doi: 10.1093/jnci/94.22.1660.

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

J Cancer Res Clin Oncol. 2004 Feb;130(2):59-72. doi: 10.1007/s00432-003-0502-2. Epub 2003 Nov 7.

STI571 (Gleevec) as a paradigm for cancer therapy.

Trends Mol Med. 2002;8(4 Suppl):S14-8. doi: 10.1016/s1471-4914(02)02305-5.

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.

Curr Opin Oncol. 2000 Nov;12(6):594-7. doi: 10.1097/00001622-200011000-00013.

Promising clinical trials on kinase inhibitor.

Trends Cell Biol. 2001 Mar;11(3):110. doi: 10.1016/s0962-8924(01)01927-4.

STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?

Tumori. 2001 Nov-Dec;87(6):S10-2.

Imatinib mesylate.

Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241.

[New molecular therapy options in hematology and oncology, exemplified by STI571].

Internist (Berl). 2001 Dec;42(12):1591-7. doi: 10.1007/s001080170011.

引用本文的文献

Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study.

Transl Gastroenterol Hepatol. 2018 Mar 14;3:16. doi: 10.21037/tgh.2018.03.01. eCollection 2018.

Targeting tumor metastases: Drug delivery mechanisms and technologies.

J Control Release. 2015 Dec 10;219:215-223. doi: 10.1016/j.jconrel.2015.09.042. Epub 2015 Sep 25.